Atossa Therapeutics Inc (ATOS)

$0.65 -0.02 (-3.25%)
Market Cap 86.92M
Revenue (ttm) 0.00
Net Income (ttm) -25.50M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 504,100
Avg Vol 617,756
Day's Range N/A - N/A
Shares Out 129.17M
Stochastic %K 3%
Beta 1.20
Analysts Strong Sell
Price Target $6.00

Latest News on ATOS

Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 10:05 AM EDT - 8 days ago

Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call Transcript

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

Mar 25, 2025, 8:00 AM EDT - 8 days ago

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Mar 20, 2025, 9:13 AM EDT - 13 days ago

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

Mar 11, 2025, 8:15 AM EDT - 22 days ago

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

Feb 5, 2025, 8:00 AM EST - 2 months ago

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No.

Jan 30, 2025, 8:17 AM EST - 2 months ago

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No.

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

Jan 23, 2025, 8:15 AM EST - 2 months ago

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

Dec 12, 2024, 8:15 AM EST - 3 months ago

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

Dec 11, 2024, 8:15 AM EST - 4 months ago

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

Dec 10, 2024, 9:05 AM EST - 4 months ago

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research

Dec 9, 2024, 8:15 AM EST - 4 months ago

Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

Nov 21, 2024, 8:30 AM EST - 4 months ago

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

Nov 20, 2024, 8:30 AM EST - 4 months ago

Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 12, 2024, 8:30 AM EST - 5 months ago

Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

Nov 5, 2024, 8:30 AM EST - 5 months ago

Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:

Nov 4, 2024, 6:30 AM EST - 5 months ago

Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:

Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen's Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

Oct 31, 2024, 8:15 AM EDT - 5 months ago

Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen's Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer

Oct 21, 2024, 8:30 AM EDT - 5 months ago

Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer

Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit

Oct 14, 2024, 5:08 PM EDT - 6 months ago

Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit

Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum

Oct 1, 2024, 8:30 AM EDT - 6 months ago

Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum

Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer

Sep 10, 2024, 8:30 AM EDT - 7 months ago

Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer

Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:30 AM EDT - 7 months ago

Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Atossa Therapeutics Granted Additional Patent Protection for Endoxifen

Aug 28, 2024, 8:30 AM EDT - 7 months ago

Atossa Therapeutics Granted Additional Patent Protection for Endoxifen

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

Aug 21, 2024, 11:30 AM EDT - 8 months ago

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations

Aug 20, 2024, 8:30 AM EDT - 8 months ago

Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations

Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 12, 2024, 8:30 AM EDT - 8 months ago

Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer

Jul 22, 2024, 8:30 AM EDT - 9 months ago

Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer

Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer

Jul 2, 2024, 4:15 PM EDT - 9 months ago

Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

Jun 28, 2024, 8:30 AM EDT - 9 months ago

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

Atossa Set to Join Russell 3000® Index Effective June 28, 2024

Jun 17, 2024, 8:30 AM EDT - 10 months ago

Atossa Set to Join Russell 3000® Index Effective June 28, 2024

Atossa to Present at the Sidoti Small-Cap Investor Conference

Jun 5, 2024, 8:30 AM EDT - 10 months ago

Atossa to Present at the Sidoti Small-Cap Investor Conference

Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

May 28, 2024, 8:30 AM EDT - 11 months ago

Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial

May 15, 2024, 8:30 AM EDT - 11 months ago

Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial

Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 13, 2024, 8:50 AM EDT - 11 months ago

Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines

May 7, 2024, 8:30 AM EDT - 11 months ago

Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines

Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen

Apr 29, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen

Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

Apr 15, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

Apr 11, 2024, 8:30 AM EDT - 1 year ago

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

Apr 9, 2024, 11:59 AM EDT - 1 year ago

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

Apr 1, 2024, 4:00 PM EDT - 1 year ago

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient

Mar 19, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

Mar 18, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors

Mar 12, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors

Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study

Feb 22, 2024, 8:30 AM EST - 1 year ago

Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study

Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial

Feb 7, 2024, 8:30 AM EST - 1 year ago

Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial

Atossa Therapeutics Issues Letter to Shareholders

Jan 9, 2024, 8:30 AM EST - 1 year ago

Atossa Therapeutics Issues Letter to Shareholders

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

Dec 4, 2023, 8:30 AM EST - 1 year ago

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

Nov 20, 2023, 8:30 AM EST - 1 year ago

Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 13, 2023, 9:00 AM EST - 1 year ago

Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors

Nov 9, 2023, 9:00 AM EST - 1 year ago

Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors